Streetbeat News

RNAZ

TransCode Therapeutics, Inc.

https://www.transcodetherapeutics.com

Industry

Biotechnology

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Several stocks experienced significant movement in Monday's mid-day session. TransCode Therapeutics, FaZe Holdings, Avalo Therapeutics, Biophytis, Cano Health, Sharps Technology, CalciMedica, TradeUP Acquisition Corp., So-Young International, Shattuck Labs, Pasithea Therapeutics, Enthusiast Gaming Holdings, InnSuites Hospitality Trust, Canopy Growth Corporation, ESS Tech, Solo Brands, Sea Limited, MDB Capital Holdings, Williams-Sonoma, Bridger Aerospace Group Holdings, MIRA Pharmaceuticals, and Energy Fuels Inc. were among the gainers. SCYNEXIS, MicroAlgo, Turbo Energy, Brainstorm Cell Therapeutics, Calidi Biotherapeutics, Rite Aid Corporation, Safe & Green Holdings Corp., Blue Star Foods Corp., GSE Systems, Morphic Holding, Solowin Holdings, Pineapple Energy, Faraday Future Intelligent Electric, AgriFORCE Growing Systems, Alector, Connexa Sports Technologies, CF Acquisition Corp. VIII, Li Auto, Tarena International, VinFast Auto, LivePerson, Editas Medicine, Coherus BioSciences, Hawaiian Holdings, and Alcoa Corporation were among the losers.

Portfolio Pulse from Lisa Levin

September 25, 2023 | 5:04 pm

U.S. stocks traded mostly higher with the Nasdaq Composite trading higher. Energy shares rose by 1.1% while utilities shares fell by 0.8%. TransCode Therapeutics, ESS Tech, and Biophytis saw their shares rise due to positive news. SCYNEXIS, Brainstorm Cell Therapeutics, and Morphic Holding saw their shares drop due to negative news.

Portfolio Pulse from Lisa Levin

September 25, 2023 | 4:12 pm

Trading of TransCode Therapeutics shares has resumed.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 3:39 pm

TransCode Therapeutics' shares resumed trading after being halted on a circuit breaker, this time to the upside. The stock is now up by 199.7%.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 3:12 pm

Several significant business events have occurred. Ford of Canada has reached a collective agreement with Unifor union, including wage increases and pension improvements. Amazon has invested $4 billion in AI startup Anthropic. PhonePe, backed by Walmart, has launched the Indus AppStore Developer Platform to challenge Google's dominance in India. Goodyear plans to redefine its operational presence in the Asia Pacific region. Pfizer's RSVpreF vaccine has been recommended by the CDC for pregnant people. Mercedes Benz has partnered with Mastercard to introduce in-car digital payments. Novartis plans to spin-off the Sandoz business. Eisai and Biogen's Alzheimer treatment Leqembi has been approved in Japan. Alcoa has appointed William F. Oplinger as President and CEO. TransCode Therapeutics' stock is trading higher after positive results with its therapeutic candidate, TTX-MC138. Tyson Foods and Perdue Farms are under investigation over alleged child labor violations. OpenAI has unveiled a new feature for its ChatGPT application, enabling verbal responses. Apple's iOS 17 update allows users to opt for a search engine other than Google. Austrian Airlines faced backlash for making inaccurate environmental claims.

Portfolio Pulse from Vandana Singh

September 25, 2023 | 2:58 pm

Shares of TransCode Therapeutics were halted on a circuit breaker to the downside, despite the stock being up 305.1%.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 2:47 pm

Shares of TransCode Therapeutics have been halted on a circuit breaker to the upside, with the stock now up 130.4%.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 1:34 pm

In Monday's pre-market session, several healthcare stocks saw significant movement. TransCode Therapeutics, Biophytis, Sunshine Biopharma, Avalo Therapeutics, PaxMedica, and Shuttle Pharmaceuticals all saw increases, with TransCode leading the gainers with a 76.2% increase. On the other hand, Brainstorm Cell, SCYNEXIS, Avinger, Alector, AcelRx Pharmaceuticals, and Elutia all saw decreases, with Brainstorm leading the losers with a 41.2% decrease.

Portfolio Pulse from Benzinga Insights

September 25, 2023 | 1:06 pm

Biophytis and Skyepharma have signed a partnership agreement for the production of Sarconeos, causing Biophytis' stock (BPTS) to rise by 45%. TransCode Therapeutics (RNAZ) announced positive pre-clinical Glioblastoma results with its lead therapeutic candidate, TTX-MC138, leading to a 30% increase in its stock. NIO Inc. (NIO) announced the closing of a US$1 billion convertible senior notes offering, resulting in an 8.5% decrease in its stock.

Portfolio Pulse from ryanfaloona@benzinga.com

September 25, 2023 | 12:41 pm

TransCode Therapeutics announced positive pre-clinical gliblastoma results with its lead candidate, TTX-MC138, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

September 25, 2023 | 12:38 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.